Premium
Identification of yeast deletions strains that alter the efficacy of antifungal drugs
Author(s) -
Bataba Eudoxie,
Serratore Nina D.,
Briggs Scott D.
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.609.5
Subject(s) - ketoconazole , antifungal drugs , drug resistance , antifungal drug , antifungal , drug , amphotericin b , biology , pathogenesis , pharmacology , medicine , intensive care medicine , immunology , microbiology and biotechnology
In recent years, a significant increase in mortality of patients with fungal infections has been observed. This is primarily due to a higher incidence of individuals who are immunocompromised including HIV‐infected patients, patients undergoing cancer therapy, organ transplant recipients, and patients with advanced stages of diabetes. A complication in treating patients with fungal infections is the development of drug resistant fungi. With the limited number of effective antifungal drugs and the increase of drug resistance, fungal infections and pathogenesis is a major threat to human health. The proposed studies help to solve this issue by identifying genes that alter antifungal drug sensitivity. Our central hypothesis is that a subset of transcriptional regulators are needed for pathways critical for altering antifungal drug resistance. This project used growth assays to determine the effects of the antifungal drugs, ketoconazole and amphotericin B, on yeast deletions strains. Overall, the proposed work will have an impact on human health related to fungal pathogenesis and drug resistance. Support or Funding Information National Science Foundation